CliniCan™: Foundations of Medical Cannabis Science, Standardization, and Clinical Practice

Tentative Agenda 

All times listed in Eastern Time (ET)

10:00 AM | Beyond the Endocannabinoid System: Understanding the Endocannabinoidome
Presented by Codi Peterson, PharmD

11:00 AM | Phytocannabinoid Pharmacology: From Mechanisms to Clinical Effects
Presented by Linda Klumpers, PhD

12:00 PM | Lunch Break
Non-accredited sponsored presentations may be offered during the lunch period and will be clearly identified separately from the accredited educational program.

12:30 PM | Cannabinoids in Clinical Practice: Evaluating the Evidence Across Therapeutic Indications
Presented by Raymond Vellky, PharmD

1:30 PM | Cannabis Formulations and Adverse Effects: Translating Pharmacology into Safer Patient Care
Presented by Melani Kane, PharmD

2:00 PM | From Evidence to Practice: Clinical Decision-Making in Cannabinoid Therapy
Presented by Melani Kane, PharmD

2:30 PM | Break

2:45 PM | Cannabis Contaminants Across the Supply Chain
Presented by Andy Krut, PharmD

3:15 PM | Equipment in Action: From Analytical Testing to the Certificate of Analysis
Presented by Jahan Marcu, PhD

3:45 PM | Cannabis Quality in Context: Industry Standards and Global Regulatory Frameworks 
Presented by Jahan Marcu, PhD

4:45 PM | Break

5:00 PM |Pharmacists at the Front Line: Advancing Safe and Effective Cannabis Care – International Pharmacist Panel
Moderated By Sangeeta Nathoo, BPharm (Hons)
Panelists: Melani Kane, PharmD; Raymond Vellky, PharmD; Andy Krut, PharmD, Codi Peterson, PharmD; Matthew Soliman, BMedSci MPharm

6:00 PM |Clinical Cannabis Roundtable: From Evidence to Practice
CliniCan Faculty 

6:30 PM | Closing Remarks

Register for CliniCan™ Foundations!
📅 February 20, 2027 | Live Virtual Event
Click Here To Register

Learning Objectives 

1. Differentiate the classical endocannabinoid system from the expanded endocannabinoidome, including its major components and roles in homeostasis.
2. Evaluate the evidence supporting the Clinical Endocannabinoid Deficiency hypothesis.
3. Analyze the pharmacodynamic properties and clinical considerations of major phytocannabinoids and commonly used cannabinoid formulations.
4. Evaluate clinically relevant cannabinoid drug interactions, drug-disease interactions, and evidence supporting the entourage hypothesis.
5. Evaluate the evidence supporting cannabinoid therapy for symptoms and conditions commonly encountered in clinical practice.
6. Assess the appropriateness of cannabinoid therapy based on patient-specific risks, contraindications, precautions, and applicable medical cannabis program requirements.
7. Differentiate cannabinoid- and formulation-specific adverse effects and their implications for therapeutic selection.
8. Apply patient-specific factors to optimize cannabinoid selection, formulation, dosing, and follow-up.
9. Design individualized cannabinoid treatment strategies for complex patient presentations using conservative dosing, titration, monitoring, and therapeutic optimization principles.
10. Identify common contaminants encountered throughout the medical cannabis supply chain and strategies used to minimize contamination.
11. Interpret cannabis certificates of analysis using relevant analytical methods, potency results, and contaminant testing data.
12. Compare regulatory frameworks governing hemp and medical cannabis across United States and international jurisdictions.
13. Describe the roles and opportunities for pharmacists across practice settings to support medical cannabis care through medication reconciliation, adverse-event monitoring, and patient education.
14. Identify evidence-based professional resources that support pharmacist practice in medical cannabis care.

Interested in Sponsoring? Check out our full sponsorship opportunities!